ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Protein > Integrin alpha V beta 5 > IT5-H82Wa

Biotinylated Human Integrin alpha V beta 5 (ITGAV&ITGB5) Heterodimer Protein, His,Avitag™&Tag Free

  • Synonym
    Integrin alpha V beta 5,ITGAV&ITGB5
  • Source
    Biotinylated Human ITGAV&ITGB5 Heterodimer Protein, His,Avitag&Tag Free(IT5-H82Wa) is expressed from human 293 cells (HEK293). It contains AA Phe 31 - Val 992 (ITGAV) & Gly 24 - Asn 719 (ITGB5) (Accession # P06756-1 (ITGAV) & P18084-1 (ITGB5)).
    Predicted N-terminus: Phe 31 (ITGAV) & Gly 24 (ITGB5)
  • Molecular Characterization
    Integrin alpha V beta 5 Structure

    Biotinylated Human ITGAV&ITGB5 Heterodimer Protein, His,Avitag&Tag Free, produced by co-expression of ITGAV and ITGB5, has a calculated MW of 114.7 kDa (ITGAV) and 81.9 kDa (ITGB5). Subunit ITGAV is fused with an acidic tail at the C-terminus and followed by a polyhistidine tag and an Avi tag (Avitag™) and subunit ITGB5 contains no tag but a basic tail at the C-terminus. The non-reducing (NR) protein migrates as 140-150 kDa (ITGAV) and 90-98 kDa (ITGB5) respectively due to glycosylation.

  • Labeling
    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
  • Protein Ratio
    Passed as determined by the HABA assay / binding ELISA.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Integrin alpha V beta 5 SDS-PAGE

Biotinylated Human ITGAV&ITGB5 Heterodimer Protein, His,Avitag&Tag Free on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
 Integrin alpha V beta 5 ELISA

Immobilized Human Vitronectin at 5 μg/mL (100 μL/well) can bind Biotinylated Human ITGAV&ITGB5 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT5-H82Wa) with a linear range of 0.01-0.156 μg/mL (QC tested).

 Integrin alpha V beta 5 ELISA

Immobilized Human Fibronectin at 5 μg/mL (100 μL/well) can bind Biotinylated Human ITGAV&ITGB5 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT5-H82Wa) with a linear range of 0.156-5 μg/mL (Routinely tested).

  • Background
    Integrin alpha V beta 5 (ITGAV & ITGB5) is expressed on a wide variety of cell types including keratinocytes, fibroblasts, adhesive monocytes, embryonic stem cells, and select endothelium and epithelium. ITGAV & ITGB5 binds ligands containing an RGD motif, notably vitronectin. Growth factors that increase PKC activity, such as VEGF or TGF alpha, promote ITGAV & ITGB5-mediated angiogenesis while alpha V beta 3, which may be expressed in the same cell, responds to FGF-basic and TNF alpha. An inhibitor of both down regulates tumor angiogenesis. During lung inflammation, up regulation of ITGAV & ITGB5 on myofibroblasts or infiltrating lymphocytes may contribute to fibrosis by freeing TGF beta from latency.
  • Clinical and Translational Updates

コメント (0)


ETD of in-stock products: 4 business days

価格(JPY) : 98,000

価格(JPY) : 425,600

人気商品のおすすめ
ストレプトアビジンコートプレート

価格(JPY) : 8,960

価格(JPY) : 38,360

ストレプトアビジン-HRP

価格(JPY) : 14,000

価格(JPY) : 33,600

Magnetic Beads™ 磁気ビーズ

価格(JPY) : 38,640

価格(JPY) : 64,400

プロモーション&展示



医薬品開発状況

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:2 Details
  • Latest Research Phase:Phase 1 Clinical

データシート&ドキュメンテーション

DMF請求
DMF (Drug Master File)

新製品

お問い合わせ&コメント

This web search service is supported by Google Inc.

totopphone